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Abstract: 
Objective: To evaluate urinary collecting system invasion (UCSI) as a prognostic parameter 
in renal cell carcinoma.  
Material and methods: 1124 patients who underwent a nephrectomy for a renal tumor at 5 
European centres were included in this retrospective study. The following variables were 
analysed: UCSI, age, sex, TNM stage, Fuhrman grade, histologic subtype, ECOG 
performance status (PS) and cancer specific survival.  
Results : There were 771 males (68.6%) and 353 females (31.4%). Median age was 61 years 
[14-88]. Median tumor size was 6 cm [1-24]. Tumors were organ confined and Furhman 
grade was recorded as I-II in 67.1% and 62.3% of the cases, respectively. Symptoms were 
present at diagnosis and ECOG-PS was ≥1 in 50.3% and 16.1% of the cases, respectively. At 
the end of follow-up 246 patients (21.9%) died from cancer. In 132 cases (11.7%), UCSI was 
noted. UCSI was associated with symptoms, TNM stage, Fuhrman grade, tumor size 
(p<0.001), ECOG-PS (p: 0.003), but not with histologic subtype (p: 0.7). In univariate 
analysis: TNM stage, Fuhrman grade, symptoms, ECOG-PS, tumor size, and UCSI (p: 
0.0001) were significant predictors for cancer specific survival. UCSI was found to be an 
independent prognostic parameter only in the setting of pT1-T2 tumors. When urinary 
collecting system was invaded, 5 and 10 years probabilities of survival were 43% and 41% 
respectively. 
Conclusion: UCSI appears as an independent prognostic parameter in organ confined RCCs. 
Our data support the need to integrate this parameter in further TNM revisions.
Introduction: 
Renal cell carcinoma (RCC) represents 2-3% of all solid neoplasms and is the third 
most common genito-urinary tumor. Clear cell histological subtype accounts for 85% of the 
RCC cases1 while the annual incidence of renal tumors is increasing in by around 3% (1.5-
5%). This may be due in part to the widespread use of imaging techniques such as ultrasound 
(US) and computerized tomography (CT)2 which allows the early detection of an increasing 
number of small renal masses.  
  The value of an accurate cancer staging system is crucial, not only for defining 
specific prognostic tools that will identify groups with greater risk of recurrence but also for 
providing cost-effective post-therapeutic surveillance protocols. TNM staging system remains 
the most useful determinant in disease classification reflecting the propensity of these tumors 
to extend locally (T), involve regional lymph nodes (N) and initiate metastatic growth (M)3. 
Although invasion of Gerota’s fascia, perirenal fat, adrenal gland, renal vein, inferior vena 
cava, and adjacent retroperitoneal structures have been extensively studied and discussed as 
prognostic variables, the prognostic value of the urinary collecting system invasion (UCSI) 
has not focused great interest in the recent RCC prognostication literature4. Invasion of the 
urinary collecting system, mentioned in the 1978 edition of the TNM classification, is no 
longer considered as a criterion for staging RCC5. However, some recent studies suggested 
that UCSI could be potentially interesting as a prognostic variable in low stage tumors 6. 
The aim of this large multicenter retrospective study was to assess the relationship 
between UCSI and usual prognostic variables in RCC and to evaluate to what extent UCSI 
should be considered as a major prognostic variable in RCC leading to further change of the 
TNM classification.  
Material and Methods 
Data retrieval 
This retrospective study included 1124 patients who underwent either radical nephrectomy or 
nephron sparing surgery for a renal tumor between 1997 and 2004. Data were extracted from 
RCC databases of 5 European academic centres: Rennes, Créteil, Saint-Etienne (France), 
Padua and Benevento (Italy). The study was approved by the IRB at each institution. Only 
tumors with malignant histology at final pathology were retained for analysis. Patients with 
metastatic disease were treated by radical nephrectomy followed by interferon, interleukin 2-
based immunotherapy according to the standards of care at that time. Post-operative follow-up 
was established according to protocols at each institution.  
 
Clinical and histological variables. 
Involvement of the urinary collecting system (UCS) was defined as evidence of invasion of 
the calices, infundibulum, pelvis or ureter; excluding simple compression or displacement by 
the primary renal mass. Tumor stage and grade were determined according to the 2002 TNM 
classification 5, and Fuhrman grading system respectively 7. Histologic subtypes were 
stratified according to the World Health Organization classification 8. All the following 
variables were recorded and analysed: age, gender, presence of symptoms at diagnosis, 
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), tumor size, TNM 
stage, Fuhrman grade, UCSI, histologic subtype, and survival data. At last follow up, patients 
were considered as living (with or without disease) or deceased (from renal cancer or from 
any other cause).  
 
 
 
Statistical analysis: 
For statistical analysis, patients were classified as ECOG 0 versus 1 or higher. Qualitative and 
quantitative variables were compared by using Chi-square (Fischer exact test) and Student t 
tests, respectively. All analyses were conducted with the statistical Package for the Social 
Sciences version 13.1 (SPSS Inc, Chicago, IL, USA), and p value significance was fixed at 
0.05. Univariate and multivariate analyses were performed by using the Kaplan-Meier and the 
Cox methods respectively. 
Results 
Patients and tumor characteristics 
This study included 1124 patients; out of them 771 were males (68.6%) and 353 were females 
(31.4%). Median age was 61 years [14-88]. Symptoms were present at diagnosis in 50.3% of 
the cases. Median tumor size was 6 cm [1-24]. Tumors were organ confined and recorded as 
Fuhrman grade 1 or 2 in 67.2% and 62.3% of the cases respectively. Surgical procedure was a 
radical nephrectomy in 896 cases (79.7%). The most common histopathological diagnosis was 
clear cell carcinoma in 875 cases (84%). Mean follow-up was 63 months. At the end of the 
follow-up, 246 patients (21.9%) died from cancer. Patient and tumor characteristics are 
summarized in Table 1. One hundred and thirty two patients (11.7%) had pathological 
evidence of UCSI.  
 
Relationship between UCSI and clinico-pathological features  
UCSI was clearly associated with aggressive clinico-pathological features. For example, when 
symptoms were present at diagnosis, UCSI was observed in 17.6% of the cases vs only 4.6% 
in incidental tumors. Similarly, when ECOC PS was recorded as 1 or more, 17.4% of the 
tumors invaded UCS vs 9.5% in case of ECOG 0. Locally advanced (T Stage ≥3) and high 
grade tumors (Fuhrman grade ≥3) were associated with more frequent UCSI (26.2% and 23.1 
%) compared to organ confined and low grade tumors (4.6% in both cases, p <0.001). In case 
of nodal invasion or distant metastases, UCSI was also more frequently noted (34.3% and 
22.3%, p <0.001). However, histological subtype had no impact on UCSI. All results 
regarding relationship between UCSI and clinico-pathological features are summarized in 
table 2.  
 
 
Survival analysis 
Evaluation of survival outcome of patients without UCSI revealed that cancer specific 
survival at 5 and 10 years was 80% and 74% respectively, while patients with UCSI had 43% 
and 41% cancer specific survival rates at 5 and 10 years respectively (Figure 1). Median 
survival time was not reached for patients without UCSI, whereas it was 60 months when the 
collecting system was invaded (p = 0.0001). Sub stratifying T stage with or without UCSI 
revealed a significant survival difference either for patients with pT1-T2 tumors (p = 0.0001), 
or for those with pT3-T4 tumors (p = 0.04) (Figure 2). When comparing pT2 tumors with 
UCSI to pT3 tumors there was no survival difference (p = 0.95).  
In univariate analysis, TNM stage, Fuhrman grade, symptoms at diagnosis, ECOG-PS, 
median tumor size and UCSI (p <0.001) appeared as significant prognostic variables for 
cancer specific survival (Table 3).  
In multivariate analysis, TNM stage, median tumor size (p <0.001), ECOG-PS (p = 0.002) 
and Fuhrman grade (p = 0.02) were independent prognostic factors. Interestingly, UCSI was 
not retained as an independent prognostic factor for the entire population (Table 3). However, 
when searching separately for independent prognostic factors in pT1-T2 and pT3-T4 tumors, 
it appeared that UCSI was an independent prognostic variable in pT1-T2 tumors while it was 
not in pT3-T4 tumors (tables 4 and 5). When both ECOG performance status and symptoms 
at diagnosis were included within the organ confined Cox model, only ECOG was retained as 
an independent prognostic parameter. When symptoms at diagnosis were included within the 
model but not ECOG performance status; both UCSI (p = 0.02) and symptoms at presentation 
(p = 0.002) were retained as independent prognostic parameters. Consistently with the current 
2002 TNM classification, perinephritic fat invasion (p <0.001) and renal vein invasion (p = 
0.01) were retained as independent prognostic factors in the setting of pT3-T4 tumors. Median 
tumor size was also found to be an additional independent prognostic parameter in pT3-T4 
tumors (Table 6). 
Discussion 
There is a consensus that TNM classification needs to be continuously revised 
according to the current state of the art in prognostication9. Large retrospective databases 
allow such a comprehensive analysis of anatomic and pathologic parameters that are the basis 
of the TNM classification. For example, the optimal tumor size cut-off for delineating T1 
from T2 tumors has been extensively discussed10. Similarly, T3 sub classification of the 2002 
TNM classification has been extensively challenged with discussion about prognostic value of 
perinephritic fat invasion versus sinus fat invasion11, adrenal gland invasion12, renal vein and 
the level of IVC invasion13. By contrast, prognostic value of UCSI has been poorly 
investigated so far.  
To our knowledge, our series is the largest series published in the literature, with a 
cohort of 1124 patients coming from 5 European academic centers and including 132 tumors 
invading the collecting system (11.7%). UCSI frequency that we reported is consistent with 
the range of the literature going from 7.5 to 14%14-17. We thus demonstrated that tumors with 
UCSI presented with higher stages and grades and were more likely to invade lymph nodes or 
exhibit distant metastases. Consistently, these tumors which were larger in size were more 
likely to be symptomatic. Interestingly, although UCSI was not retained as an independent 
prognostic parameter overall, it was retained as an independent prognostic variable in pT1-T2 
stage tumors. It suggests that pathological parameters such as renal vein invasion or 
perinephritic fat invasion are more important outcome predictors than UCSI in locally 
advanced tumors. Conversely, it suggests that UCSI, together with tumor size, ECOG 
performance status and symptoms could be an additional important prognostic variable in 
organ confined renal tumors. Interestingly we previously demonstrated that symptoms as well 
as tumor size were able to stratify T1-T2 tumors18. This additional data could provide some 
rationale for using tumor size, symptoms and UCSI for sub stratifying T1-T2 tumors similarly 
to that of fat, adrenal and renal vein invasion which are defining T3a, b and c stages in locally 
advanced tumors. We and others also demonstrated that tumors associated with symptoms at 
diagnosis were larger in size, of higher grades and exhibited poorer outcome19. Therefore, 
local symptoms such as haematuria could be viewed as surrogate indicators for UCSI. 
However, interestingly the present study highlighted the independent prognostic value of 
pathological invasion of UCS even after adjustment for tumor size, ECOG performance status 
or symptoms. It means that UCSI has an intrinsic biological significance in organ confined 
tumors, similarly to that of renal vein or capsular invasion in locally advanced disease. A 
tumor crossing an anatomic natural barrier such as collecting system should not be longer 
considered as an organ confined tumor. This is supported by the fact that we found no 
survival difference between pT2 tumors exhibiting UCSI and pT3 tumors. It should therefore 
be taken into account for further TNM classification.  
Only 4 studies have focused on UCSI prognostic significance so far. In 2002, Uzzo et 
al analyzed the outcome of  61 patients with tumors invading UCS in RCC14. They concluded 
that these tumors although exhibiting higher stages and grades had not a significantly poorer 
outcome. It was noticed that even though UCSI in organ confined RCCs was uncommon, 
there was a trend for a worse prognosis when it occurred. However, the independent 
prognostic value of UCSI was not assessed through multivariate analyses in this study. By 
analyzing 124 tumors invading the UCS in 895 patients, Palapattu et al reported a high 
proportion of large (2/3 were classified as pT3) and symptomatic tumors within this 
population. UCSI was also significantly associated with lymph node invasion and presence of 
distant  metastases at diagnosis15. Univariate analysis revealed a 1.96 time increased risk of 
death for patients with UCSI. Interestingly, the authors noticed a significantly worse 
prognosis in patients with T1 and T2 tumors with UCSI. Recently, the same group analyzed 
the outcome of 39 patients with UCSI in stage I and II RCCs17. No association was found 
between UCSI, T stage, Fuhrman grade, tumor size, ECOG-PS, capsular involvement and 
histological type. Univariate analysis confirmed a worse prognosis when UCS was invaded, 
resulting in a significantly poorer survival in this subgroup of patients. Furthermore 
consistently with our study, multivariate analysis revealed UCSI as an independent prognostic 
factor within organ confined tumors, with a 3.78 times increased risk of tumor recurrence. 
Finally, Terrone et al  obtained comparable results except that adverse outcome associated 
with UCSI was only observed within the pT2 category16. The current series dealing with 
UCSI prognostic value are summarized in table 7.  
Even though TNM staging remains the most widely recognized prognostic system it is 
important to further identify independent prognostic variables that are able either to improve 
the system itself or that can be integrated within more sophisticated prognostic tools. The 
common goal of identifying new prognostic variables is to improve the predictive accuracy of 
current prognostic systems that we dispose. Based on our results, we believe that UCSI could 
fit with such an objective for organ confined tumors. Based on the current TNM 
classification, organ confined renal tumors are only stratified based on tumor size. No reliable 
biological prognostic variable has been indentified so far in the setting of localized RCC. 
Therefore, information regarding UCSI could be either integrated within further TNM 
classification revision or being tested for incorporated within new nomograms specially 
designed for localized RCC. Finally, our study besides new insights in localized RCC 
prognostication also suggests that a closer follow up should be proposed for those patients 
with organ confined tumors a nd UCSI by contrast with what is usually proposed in such low 
stage RCCs20.  
Our study is not exempt of limitations. The main drawback is that due to its 
retrospective character and to the lack of central pathological review, some critical 
information may have been missed. Notably, it could be argued that since UCSI has not been 
prospectively searched, only massive UCSI associated with large tumors has been reported. 
Then less obvious UCSI either microscopic or limited may have been missed even though it 
was present, therefore leading to a selection bias of more aggressive tumors. Additionally, 
because our study was based on retrospective pathological reports analysis, it could be 
hypothesized that this information was more likely to be noted in larger tumors that had been 
treated by radical nephrectomy rather than in small tumours treated by nephron sparing 
surgery. Our low NSS rate pleads for this hypothesis. Therefore by searching for CSI 
information based on the current pathological analysis practice we biased for larger tumors 
which are more likely to be symptomatic. Our 50% symptomatic tumors rate which is a little 
bit higher than usually reported is also consistent with this hypothesis. Finally, it could also be 
argued that less attention is paid for CSI in small renal tumor specimens and that CSI is more 
difficult to assess following partial nephrectomy. It is probably true, however even though the 
size of tumor margins does not matter, careful examination of the quality of the tumor 
surrounding tissue is usually performed. Therefore, the presence or absence of urothelium 
tissue along with its invasion should be easily identified. Urologists should also mention 
whether or not collecting system has been entered and if there is any CSI suspicion.  
Conclusion 
 
Tumors with UCSI are associated with most adverse clinical and pathological parameters in 
RCC. Based on the present study, we recommend that urinary collecting system invasion 
should be systematically identified and recorded in pathological reports. UCSI appears as a 
new important prognostic factor for organ confined tumors. This pathologic parameter should 
be considered for further TNM classification revisions and for its integration within new 
prognostic nomograms. Finally, a closer follow-up should be proposed to patients operated on 
for organ confined tumors and exhibiting UCSI. To what extend organ confined tumors with 
associated UCSI should be considered as locally advanced tumors and proposed for adjuvant 
trials needs to be further explored. 
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